Genedx Holdings (WGS) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Genedx Holdings Corp   (NASDAQ: WGS)

Genedx Holdings 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Genedx Holdings in the second quarter 2026?
Genedx Holdings Corp recorded a cumulative net loss of $-106 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -38.72%.

Within the Medical Equipment & Supplies industry 104 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2934 to 2979.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -11.88 % -1.27 % 25.66 % 42.91 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -106 -78 -21 2 1
Return On Equity (TTM) -38.72 % -27.5 % -7.41 % 0.78 % 0.57 %
WGS's Total Ranking # 2979 # 2934 # 1917 # 226 # 1971
Equity (TTM) in Millions 244 254 308 292 277
Seq. Equity Change -3.9 % -17.54 % 5.45 % 5.46 % 7.66 %
Seq. Net Income Change - - - - -

Back to WGS Management Effectiveness >> WGS's 5 Years Annual ROE >> Compare WGS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 105
Sector # 360
Overall # 2979

Return On Equity Statistics
High Average Low
0.78 %
-31.82 %
-63.52 %
(Sep 30 2025)   (Dec 31 2023)



  News about Genedx Holdings Corp Return on Equity ROE

GeneDx Holdings Corp. Evolving Genetic Testing to Deliver Remarkable Growth and Investor Returns

GeneDx Holdings Corp. (NASDAQ: WGS) has emerged as a formidable player in the field of genetic testing, witnessing a staggering 1,101% surge in its stock price this year. This remarkable rise can be attributed to the company s strategic shift towards more comprehensive exome/genome testing and consistently achieving record high margins. With such impressive growth, GeneDx has firmly established itself as a top-performing stock on the Russell 2000 index. Let s delve deeper into the factors driving the success of this momentum stock and why investors should take note of GeneDx Holdings Corp. s future potential.Expanding into Exome/Genome TestingGeneDx s outstanding performance in 2024 is largely a result of its successful pivot towards exome/genome testing. This shift played a vital role in generating substantial revenue growth for the company. By offering comprehensive genetic testing services to healthcare providers, GeneDx has become an industry leader in the field. The increasing demand for personalized medicine and the rise in genetic disease screenings have further fueled the company s growth trajectory.



WGS Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 308 245 228 254 388
Y / Y Equity Change 25.66 % 7.56 % -10.13 % -34.63 % -
Net Income in Millions -21 -52 -176 -549 -245
Y / Y Net Income Change - - - - -
Return On Equity -6.82 % -21.32 % -77.09 % -216.39 % -63.23 %

Back to WGS Management Effectiveness >> WGS's 5 Years Annual ROE >> Compare WGS ROE to its Competitors




More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
WGS's' Return on Equity at Yahoo Finance
WGS's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for WGS's Competitors
Subscribers only: Roe for Genedx Holdings 's Suppliers
Subscribers only: Return On Equity for WGS's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-13T23:50:17+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.